Education
About Us
Working with TipRanks
Follow Us
Cerus Corporation (CERS)
NASDAQ:CERS
CERS Stock Chart & Stats
$1.80
-$0.02(-1.22%)
At close: 4:00 PM EST
$1.80
-$0.02(-1.22%)
Day’s Range― - ―
52-Week Range$1.12 - $2.96
Previous CloseN/A
Volume302.69K
Average Volume (3M)1.88M
Market Cap
$330.54M
Enterprise Value$407.52M
Total Cash (Recent Filing)$82.88M
Total Debt (Recent Filing)$96.95M
Price to Earnings (P/E)―
Beta1.74
Next Earnings
Apr 30, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding192,171,780
10 Day Avg. Volume2,619,531
30 Day Avg. Volume1,879,362
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)6.11
Price to Sales (P/S)1.90
P/FCF Ratio46.07
Enterprise Value/Market Cap1.23
Enterprise Value/Revenue1.98
Enterprise Value/Gross Profit3.63
Enterprise Value/Ebitda-53.88
Forecast
1Y Price Target
$5.00Price Target Upside177.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.07
Revenue Forecast (FY)$251.73M
Bulls Say, Bears Say
Bulls Say
IFC Adoption And Scalable ManufacturingAnalyst observes that growing adoption of the Intercept Fibrinogen Complex, combined with a kit-based blood‑center manufacturing model, should improve scalability, lower hospital inventory costs, and shift sales toward kits for blood centers.
National Distribution PartnershipAnalyst highlights the group purchasing agreement with Blood Centers of America as a national distribution channel that enables broader and more efficient access to INTERCEPT products through established logistics and shared infrastructure.
Regulatory Approvals In EuropeAnalyst notes that CE Mark approval for the next-generation LED illuminator and an ongoing European regulatory review for the red blood cell product create a pathway to expand system and product sales across Europe.
Bears Say
Limited Penetration And Valuation ConstraintAnalyst cautions that relatively low penetration within independent blood centers, together with a stock trading roughly in line with small‑cap peers on sales, may limit near-term upside if expansion efforts do not succeed.
Margin Pressure From CostsAnalyst warns that inflationary pressures, continued tariff impacts, and higher therapeutic production costs are compressing gross margins and weighing on profitability.
Regulatory Dependence RiskAnalyst points out that company performance depends heavily on regulatory approval of the red blood cell program in Europe, making the stock sensitive to that regulatory outcome.
Cerus News
CERS FAQ
What was Cerus Corporation’s price range in the past 12 months?
Cerus Corporation lowest stock price was $1.12 and its highest was $2.96 in the past 12 months.
What is Cerus Corporation’s market cap?
Cerus Corporation’s market cap is $330.54M.
When is Cerus Corporation’s upcoming earnings report date?
Cerus Corporation’s upcoming earnings report date is Apr 30, 2026 which is in 38 days.
How were Cerus Corporation’s earnings last quarter?
Cerus Corporation released its earnings results on Mar 02, 2026. The company reported -$0.01 earnings per share for the quarter, missing the consensus estimate of -$0.008 by -$0.002.
Is Cerus Corporation overvalued?
According to Wall Street analysts Cerus Corporation’s price is currently Undervalued.
Does Cerus Corporation pay dividends?
Cerus Corporation does not currently pay dividends.
What is Cerus Corporation’s EPS estimate?
Cerus Corporation’s EPS estimate is -0.04.
How many shares outstanding does Cerus Corporation have?
Cerus Corporation has 192,171,780 shares outstanding.
What happened to Cerus Corporation’s price movement after its last earnings report?
Cerus Corporation reported an EPS of -$0.01 in its last earnings report, missing expectations of -$0.008. Following the earnings report the stock price went down -15.81%.
Which hedge fund is a major shareholder of Cerus Corporation?
Currently, no hedge funds are holding shares in CERS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cerus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (177.78% Upside)
$5.00 (177.78% Upside)
Blogger Sentiment
Bullish
CERS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $202.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.4%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.03%
12-Months-Change
Fundamentals
Return on Equity
-26.42%
Trailing 12-Months
Asset Growth
10.42%
Trailing 12-Months
Company Description
Cerus Corporation
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
CERS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call conveyed a predominantly positive commercial and financial momentum: record revenues (+16% YoY), strong product and EMEA growth, rapidly expanding IFC demand and continued positive adjusted EBITDA and cash runway. Key strategic milestones were achieved including CE Mark and commercial launch of INT200, completion of U.S. RedeS enrollment, and a major group purchasing agreement with BCA that could materially expand U.S. penetration. Offsetting these positives are margin compression driven by higher IFC production costs, import tariffs and inflation, an expected taper in BARDA-reimbursed R&D revenue as the contract expires, and ongoing regulatory/timing uncertainties for RBC approvals. Overall, the positives (strong revenue and demand growth, improving profitability metrics, strategic partnerships and product launches) outweigh the challenges, while management continues to highlight areas of uncertainty that could affect near-term margins and timing.View all CERS earnings summariesCERS Stock 12 Month Forecast
Average Price Target
$5.00
▲(177.78% Upside)
Technical Analysis
Tactile Systems Technology
―
Viemed Healthcare
―
Brainsway
―
Outset Medical
―
908 Devices
―
Ownership Overview
5.74% Insiders
13.78% Mutual Funds
34.40% Other Institutional Investors
26.10% Public Companies and
Individual Investors